If you are considering tesamorelin therapy, knowing what the process looks like can help you feel confident about taking the next step. Here is a general overview of what patients at Formation experience when starting treatment.
Initial Consultation: Your journey begins with an in-depth consultation with Dr. Gopal Grandhige. During this visit, you will discuss your goals, review your health history, and determine whether tesamorelin is the right fit for you. Lab work may be ordered to assess your baseline growth hormone levels and overall metabolic health.
Personalized Treatment Plan: Once Dr. Grandhige confirms that you are a good candidate, a customized treatment plan is developed. This plan includes your tesamorelin dosing protocol, injection schedule, and any complementary therapies that may enhance your results. For patients who also want to address stubborn fat through surgical options, Formation offers procedures like high definition liposuction and abdominoplasty for men that can work alongside peptide therapy.
Nutrition Strategy: Your concierge dietician will work with you to create a nutrition plan that complements your peptide therapy. This is tailored to your preferences, lifestyle, and specific body composition goals.
Ongoing Monitoring: Tesamorelin therapy is not a “set it and forget it” treatment. Regular follow-up appointments allow Dr. Grandhige and his team to track your progress, review lab results, and make adjustments to your protocol as needed. This level of monitoring ensures that you are getting the most out of your treatment while minimizing any potential side effects.
Realistic Timeline: Most patients begin to notice changes in body composition within the first four to eight weeks of consistent treatment. Significant reductions in visceral fat are typically observed over a period of three to six months. Patience and consistency are key, and having a dedicated medical team behind you makes the process far more manageable.
Tesamorelin is a powerful tool for reducing visceral fat and reshaping your body composition when used under proper medical guidance. However, the difference between seeing real results and putting your health at risk often comes down to two factors: where your medication comes from and who is overseeing your treatment. At Formation in Tampa, Dr. Gopal Grandhige, a board-certified general surgeon, ensures that every patient receives human-grade tesamorelin sourced from licensed compounding pharmacies, not the unregulated, research-grade peptides flooding online marketplaces. Combined with a concierge dietician who tailors your nutrition plan to work hand in hand with your peptide therapy, you get a level of coordinated care that simply is not available through a website or a self-directed approach. The clinic also offers advanced PDO thread lift treatments and other services that can further enhance your overall results.
References:
Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://pubmed.ncbi.nlm.nih.gov/20554713/
National Institute of Diabetes and Digestive and Kidney Diseases. (2018). Tesamorelin. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548730/
Russo, S. C., Ockene, M. W., Arpante, A. K., Johnson, J. E., Lee, H., Toribio, M., Stanley, T. L., Hadigan, C. M., Grinspoon, S. K., Erlandson, K. M., & Fourman, L. T. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://pubmed.ncbi.nlm.nih.gov/38905488/
Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://pubmed.ncbi.nlm.nih.gov/25038357/